GLP-1 implants for obese cats could revolutionize pet weight loss

A new study could bring weight loss drugs for pets one step closer to reality. Okava Pharmaceuticals has launched a pilot programme testing a GLP-1 treatment for obese cats. The trial uses injectable implants that slowly release the medication over six months, offering a more convenient alternative to weekly injections.

Obesity and diabetes affect millions of pets in the U.S., with around 60% of cats and dogs classified as overweight. Hundreds of thousands also suffer from diabetes, mirroring trends seen in humans. Drugs like Ozempic and Wegovy have surged in popularity among people, with roughly one in eight American adults trying them for weight loss or diabetes management.

Okava's study involves cats receiving small implants that deliver the drug continuously. This approach differs from human treatments, which typically require regular injections. If successful, the results—expected next summer—could pave the way for a new veterinary treatment.

Some vets already prescribe human GLP-1 drugs off-label for diabetic cats. However, no company has yet secured approval for a pet-specific version. Okava aims to make its product accessible by pricing it at or below $100 per month, addressing concerns about affordability.

The long-term appeal of such treatments remains unclear. Food plays a central role in pet care, and owners may hesitate to adopt medication-based solutions. Practical challenges, like ease of administration and cost, will also determine whether these drugs gain traction in the veterinary market.

The pilot study's findings will reveal whether GLP-1 implants could become a viable option for pet obesity. If approved, the treatment might offer a simpler, long-lasting alternative to current methods. Success would depend on balancing effectiveness, convenience, and affordability for pet owners.